{"transactions":[{"id":2222716,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":1,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-23T22:47:26.000Z","date":"2022-06-23","kind":"sale","acquired":false,"shares":29631,"price":13.0036,"value":385309.6716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.72 to $13.35, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways Holdings Limited (\"Globeways\") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":537392,"source":{"system":"sec-edgar","filing":"0001104659-22-073980","document":"tm2219298-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922073980/tm2219298-1_4seq1.xml","form_type":"4"}},{"id":2222715,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":1,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-23T22:47:26.000Z","date":"2022-06-22","kind":"sale","acquired":false,"shares":49953,"price":12.7035,"value":634577.9355,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.35 to $12.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways Holdings Limited (\"Globeways\") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":567023,"source":{"system":"sec-edgar","filing":"0001104659-22-073980","document":"tm2219298-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922073980/tm2219298-1_4seq1.xml","form_type":"4"}},{"id":2222714,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":1,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-23T22:47:26.000Z","date":"2022-06-21","kind":"sale","acquired":false,"shares":22319,"price":12.7662,"value":284928.8178,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.58 to $12.99, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways Holdings Limited (\"Globeways\") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":616976,"source":{"system":"sec-edgar","filing":"0001104659-22-073980","document":"tm2219298-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922073980/tm2219298-1_4seq1.xml","form_type":"4"}},{"id":2906899,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":1511966,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are owned directly by F2 MC, LLC (\"F2 MC\"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214798},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906898,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":503988,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are owned directly by F2 Bio TD, LLC (\"F2 Bio\"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":71599},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906897,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":1007977,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by F2 MG Limited (\"F2 MG\"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":143198},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906896,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":503988,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":71599},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906895,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":1282051,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by F2 MG Limited (\"F2 MG\"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":182135},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906894,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":3205128,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":455338},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906893,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":4500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":639295},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906892,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":20500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2912345},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906891,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":8000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Globeways Holdings Limited (\"Globeways\"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1136525},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906890,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"purchase","acquired":true,"shares":104762,"price":21,"value":2200002.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are owned directly by F2 GC LLC (\"F2 GC\"). Globeways II is the appointed manager of F2 GC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":104762,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906889,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"purchase","acquired":true,"shares":95238,"price":21,"value":1999998.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":622175,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906888,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":214798,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are owned directly by F2 MC, LLC (\"F2 MC\"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":214798,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906887,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":71599,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are owned directly by F2 Bio TD, LLC (\"F2 Bio\"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":71599,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906886,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":143198,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by F2 MG Limited (\"F2 MG\"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":325333,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906885,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":71599,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":526937,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906884,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":182135,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by F2 MG Limited (\"F2 MG\"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":182135,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906883,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":455338,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":455338,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906882,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":639295,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":639295,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906881,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":2912345,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2912345,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906880,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":1136525,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Globeways Holdings Limited (\"Globeways\"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1136525,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}}]}